Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-018-2522-5
Abstract: PurposeCYP3A4, CYP2C19, and CYP3A5 are primarily involved in the metabolism of cilostazol. We investigated the effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its two active metabolites.MethodsThirty-three healthy Korean volunteers… read more here.
Keywords: polymorphisms pharmacokinetics; cyp2c19 cyp3a5; active metabolites; cyp3a5 genetic ... See more keywords